
Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.
What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc. (NASDAQ:INMB), a clinical-stage biotechnology company that is focused on using a patient’s immune system to fight cancers.